The estimated Net Worth of Percy H. Carter is at least $4.78 Milione dollars as of 5 June 2024. Dr Carter owns over 4,000 units of Blueprint Medicines Corp stock worth over $3,626,431 and over the last 3 years he sold BPMC stock worth over $1,155,995.
Dr has made over 6 trades of the Blueprint Medicines Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 4,000 units of BPMC stock worth $420,520 on 5 June 2024.
The largest trade he's ever made was selling 4,000 units of Blueprint Medicines Corp stock on 5 June 2024 worth over $420,520. On average, Dr trades about 1,245 units every 66 days since 2021. As of 5 June 2024 he still owns at least 41,895 units of Blueprint Medicines Corp stock.
You can see the complete history of Dr Carter stock trades at the bottom of the page.
Dr. Percy H. Carter M.B.A., Ph.D. is the Chief Scientific Officer at Blueprint Medicines Corp.
Dr D is 51, he's been the Chief Scientific Officer of Blueprint Medicines Corp since . There are 16 older and 13 younger executives at Blueprint Medicines Corp. The oldest executive at Blueprint Medicines Corp is Mark Goldberg, 65, who is the Independent Director.
Percy's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 10 years, insiders at Blueprint Medicines Corp have traded over $126,865,732 worth of Blueprint Medicines Corp stock and bought 131,110 units worth $2,599,105 . The most active insiders traders include Llc Fmr, Kevin P Starr e Lonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of $1,362,195. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth $1,685,900.
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
Blueprint Medicines Corp executives and other stock owners filed with the SEC include: